19. A pharmaceutical composition comprising an antibody, or antigen-binding fragment thereof, according to any one of claims 1, 2, and 9-18, and a pharmaceutically acceptable carrier or excipient.

~~20. A method for reducing deposition of extracellular matrix in a subject in need thereof, said method comprising administering to said subject an effective amount of a pharmaceutical composition of claim 19, thereby inhibiting excessive deposition of extracellular matrix in a subject.~~

~~21. A method for preventing or treating a disease, disorder or condition mediated by PDGF-B binding to PDGFR$\beta$, said method comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition of claim 19.~~

~~22. The method of claim 21, wherein said disease, disorder or condition is at least one selected from the group consisting of: atherosclerosis, restenosis, pulmonary hypertension, retinal vascular disease, cardiac fibrosis, lung fibrosis, liver fibrosis, kidney fibrosis, systemic sclerosis, rheumatoid arthritis, osteoarthritis, and tumorigenesis.~~

230. An antibody, or antigen binding fragment thereof, of any one of claims 1, 2, 9-18, or a pharmaceutical composition of claim 19, for use in reducing deposition of extracellular matrix in a subject in need thereof.

241. An antibody, or antigen binding fragment thereof, of any one of claims 1, 2, 9-18, or a pharmaceutical composition of claim 19, for use in preventing or treating a disease, disorder or condition mediated by PDGF-B binding to PDGFR$\beta$.

252. Use of an antibody, or antigen binding fragment thereof, of any one of claims 1, 2, 9-18, or a pharmaceutical composition of claim 19, in the manufacture of a medicament for reducing deposition of extracellular matrix in a subject in need thereof.

263. Use of an antibody, or antigen binding fragment thereof, of any one of claims 1, 2, 9-18, or a pharmaceutical composition of claim 19, in the manufacture of a medicament preventing or treating a disease, disorder or condition mediated by PDGF-B binding to PDGFR$\beta$.